Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities

NCT00454077 is registered in ClinicalTrials.gov with University of Siena as lead sponsor.

NCT NCT00454077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00454077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities
Lead sponsor
University of Siena
Phase
Observational
Overall status
Completed
Start date
December 31, 2004
Completion date
September 30, 2006
Enrollment
72
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer